Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal
June 22, 2024 at 13:40 PM EDT
FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting protein-tyrosine kinase 7 candidate to Day One Biopharma.
